ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custo ...
Finding an effective treatment for osteosarcoma, the most common type of bone cancer in children and young adults, has ...
A phase 2 study of Pfizer’s atirmociclib has hit its primary endpoint, providing evidence that the CDK4 inhibitor improves progression-free survival (PFS) in second-line metastatic breast cancer. But ...
Extended long-term survival observed after an additional year of follow-up in ongoing phase 2a clinical trial, with 50% of 46 patients with advanced non-small cell lung cancer (NSCLC) treated with agl ...
A 1951 CIA report on parasites and tumors spread online in March 2026 — but it was declassified years ago and does not reveal ...
Dortmund, Germany, March 17, 2026 - iDEL Therapeutics today announced the closing of a EUR 9 million seed financing, ...
A cross-sectional study of 651 middle-aged breast cancer patients in China found that 21.2% experienced clinically relevant fatigue during ...
Implementing a simple exercise plan during chemotherapy may ease cognitive impairment and fatigue, promoting better health ...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces two "trial in progress" presentations at the 2026 European Association of Urology congress (EAU) in London, UK. These trials investigate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results